• Ritu Verma
• Naveen Kumar
• Shailesh Upadheyay
• Swati
• Dheeraj Kumar

Migraine management in pregnancy presents unique challenges, and the use of triptans—a common class of migraine medications—adds a layer of complexity due to concerns about fetal safety. This paper explores the intricacies of migraine management during pregnancy, focusing on the dilemma surrounding the use of triptans. Through a comprehensive review of existing literature, clinical studies, and case reports, we aim to unravel the complexities associated with triptan use in pregnant women with migraines. The paper provides insights into the current guidelines, the risk-benefit analysis, and gaps in research, offering a nuanced perspective on the triptan dilemma in the context of pregnancy. Triptans are a class of tryptamine-based drugs that are administered to alleviate migraine headaches. The triptans act as serotonin (5-hydroxytriptamine) (5-HT) agonists by binding to various serotonin receptors, which reduce migraine pain by neuronal inhibition and vasoconstriction. As of right now, seven different types of triptans are available on the American market: frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan, and almotriptan. The purpose of this study was to look at the effects of triptans on pregnancy. Although the makers of three of the drugs have pregnancy registries, there hasn't been much research done on the use of triptans during pregnancy. There is significantly more information available on the use of sumatriptan during pregnancy because it has been on the market longer than other triptans and may have a bigger market share. There appears to be a higher incidence of preterm births, however no triptan has been shown to be teratogenic.

Pharmaceutical therapy, physiopathology, pregnancy, agonists of serotonin absorption, serotonin receptor, 5-HT, pharmacology, unfavorable pharmacological effects, migraine condition

"MIGRAINE MANAGEMENT CHALLENGES IN PREGNANCY: UNRAVELING THE TRIPTAN DILEMMA", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 2, page no.f805-f810, February-2024, Available :http://www.jetir.org/papers/JETIR2402597.pdf

"MIGRAINE MANAGEMENT CHALLENGES IN PREGNANCY: UNRAVELING THE TRIPTAN DILEMMA", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 2, page no. ppf805-f810, February-2024, Available at : http://www.jetir.org/papers/JETIR2402597.pdf